TY  - BOOK
AU  - Herrington,William G.
AU  - Staplin,Natalie
AU  - Wanner,Christoph
AU  - Green,Jennifer B.
AU  - Hauske,Sibylle J.
AU  - Emberson,Jonathan R.
AU  - Preiss,David
AU  - Judge,Parminder
AU  - Mayne,Kaitlin J.
AU  - Ng,Sarah Y.A.
AU  - Sammons,Emily
AU  - Zhu,Doreen
AU  - Hill,Michael
AU  - Stevens,Will
AU  - Wallendszus,Karl
AU  - Brenner,Susanne
AU  - Cheung,Alfred K.
AU  - Liu,Zhi-Hong
AU  - Li,Jing
AU  - Hooi,Lai Seong
AU  - Liu,Wen
AU  - Kadowaki,Takashi
AU  - Nangaku,Masaomi
AU  - Levin,Adeera
AU  - Cherney,David
AU  - Maggioni,Aldo P.
AU  - Pontremoli,Roberto
AU  - Deo,Rajat
AU  - Goto,Shinya
AU  - Rossello,Xavier
AU  - Tuttle,Katherine R.
AU  - Steubl,Dominik
AU  - Petrini,Michaela
AU  - Massey,Dan
AU  - Eilbracht,Jens
AU  - Brueckmann,Martina
AU  - Landray,Martin J.
AU  - Baigent,Colin
AU  - Haynes,Richard
TI  - Empagliflozin in Patients with Chronic Kidney Disease
PY  - 2023///-01-12
KW  - Text
KW  - local
N1  - /pmc/articles/PMC7614055; /pubmed/36331190
N2  - BACKGROUND: This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. METHODS: We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus matching placebo. Eligibility required an estimated glomerular filtration rate (eGFR) of ≥20 to <45 ml/minute/1.73m(2); or ≥45 to <90 ml/minute/1.73m(2) with a urinary albumin-to-creatinine ratio (ACR) of ≥200 mg/g. The primary outcome was a composite of kidney disease progression (end-stage kidney disease, a sustained eGFR <10 ml/minute/1.73m(2), a sustained decline in eGFR of ≥40%, or a renal death) or death from cardiovascular causes. RESULTS: During a median of 2.0 years follow-up, a primary outcome event occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% CI 0.64 to 0.82; P<0.001), with consistent results in those with or without diabetes and across the range of eGFR studied. There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003), but no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%), or death from any cause (4.5% vs 5.1%). The rates of serious adverse events were broadly similar in the two groups. CONCLUSIONS: Empagliflozin reduced the risk of the composite outcome of kidney disease progression or cardiovascular death in a wide range of patients at risk of CKD progression. (Funding:Boehringer Ingelheim, Eli Lilly and others; Clinicaltrials.gov:NCT03594110, EuDRACT: 2017-002971-24)
UR  - http://dx.doi.org/10.1056/NEJMoa2204233
ER  -